Table 1.
Summary data for all patients (n = 190) receiving HDR-BT, EBRT, or both
| Variable | HDR-BT | EBRT | Both | p Value* |
|---|---|---|---|---|
| Number of patients | 37 | 141 | 12 | |
| Mean age (years) | 57 | 56 | 69 | 0.64 |
| Sex (number of patients) | 0.71 | |||
| Male | 21 | 74 | 5 | |
| Female | 16 | 67 | 7 | |
| Mean duration of symptoms (months) | 6.87 | 9.9 | 27.2 | 0.09 |
| Mean tumor volume (cm3) | 644.6 | 640.5 | 1194.1 | 0.9 |
| Grade (number of patients) | 0.006 | |||
| Low | 2 | 1 | 1 | |
| Intermediate | 7 | 9 | 3 | |
| High | 28 | 131 | 8 | |
| Depth (number of patients) | 0.12 | |||
| Superficial to fascia | 9 | 18 | 1 | |
| Deep to fascia | 28 | 123 | 11 | |
| Stage (number of patients) | 0.80† | |||
| IIA | 2 | 9 | 0 | |
| IIB | 8 | 18 | 0 | |
| IIC | 0 | 4 | 1 | |
| III | 25 | 101 | 10 | |
| IV | 2 | 9 | 1 | |
| Primary versus recurrent (number of patients) | 0.6 | |||
| Primary | 37 | 138 | 11 | |
| Recurrent | 0 | 3 | 1 | |
| Mean total radiotherapy dose (Gy) | 33.4 | 62.3 | 54.8 | < 0.0001 |
| Mean duration of treatment (days) | 5.3 | 54.5 | 41.7 | < 0.0001 |
| Mean duration of followup (months) | 10.6 | 50.2 | 12.7 | < 0.0001 |
| Local recurrence (number of patients) | 3 (8%) | 15 (11%) | 2 (17%) |
* For HDR-BT versus EBRT; †results for pooled Stage II patients; HDR-BT = high-dose-rate brachytherapy; EBRT = external-beam radiotherapy.